These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25969354)

  • 1. Histochemical evidence of zoledronate inhibiting c-src expression and interfering with CD44/OPN-mediated osteoclast adhesion in the tibiae of mice.
    Liu H; Cui J; Sun J; Du J; Feng W; Sun B; Li J; Han X; Liu B; Yimin ; Oda K; Amizuka N; Li M
    J Mol Histol; 2015 Jun; 46(3):313-23. PubMed ID: 25969354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronate promotes bone formation by blocking osteocyte-osteoblast communication during bone defect healing.
    Cui P; Liu H; Sun J; Amizuka N; Sun Q; Li M
    Histol Histopathol; 2018 Jan; 33(1):89-99. PubMed ID: 28345127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histochemical evidence of osteoclastic degradation of extracellular matrix in osteolytic metastasis originating from human lung small carcinoma (SBC-5) cells.
    Li M; Amizuka N; Takeuchi K; Freitas PH; Kawano Y; Hoshino M; Oda K; Nozawa-Inoue K; Maeda T
    Microsc Res Tech; 2006 Feb; 69(2):73-83. PubMed ID: 16456838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effects of zoledronate on the histomorphology of osteoclast in young albino rats.
    Ralte S; Khatri K; Nagar M
    Ann Anat; 2011 Dec; 193(6):509-15. PubMed ID: 21530208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
    Pozzi S; Vallet S; Mukherjee S; Cirstea D; Vaghela N; Santo L; Rosen E; Ikeda H; Okawa Y; Kiziltepe T; Schoonmaker J; Xie W; Hideshima T; Weller E; Bouxsein ML; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2009 Sep; 15(18):5829-39. PubMed ID: 19737962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression.
    Chellaiah MA; Kizer N; Biswas R; Alvarez U; Strauss-Schoenberger J; Rifas L; Rittling SR; Denhardt DT; Hruska KA
    Mol Biol Cell; 2003 Jan; 14(1):173-89. PubMed ID: 12529435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice.
    Kuroshima S; Go VA; Yamashita J
    Endocrinology; 2012 Jan; 153(1):17-28. PubMed ID: 22109892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on the effects of zoledronic-acid-loaded collagen membrane on bone metabolism cells].
    Meng YH; Peng Y; Liu D; Chen Y; Wang H; Liang X
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2011 Feb; 46(2):107-11. PubMed ID: 21426781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
    Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
    Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical, pharmacologic, and in vitro cellular effects of loading collagen membranes with zoledronic acid.
    Liao J; Meng Y; Zhai J; Wen C; Ten M; Tian A; Wang Y; Liang X
    Int J Oral Maxillofac Implants; 2013; 28(4):1027-36. PubMed ID: 23869361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
    Schindeler A; Little DG
    Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Effects of Local and Systemic Zoledronic Acid Application on Mandibular Distraction Osteogenesis.
    Dundar S; Artas G; Acikan I; Yaman F; Kirtay M; Ozupek MF; Asutay F; Kom M
    J Craniofac Surg; 2017 Oct; 28(7):e621-e625. PubMed ID: 28708644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibronectin inhibits osteoclastogenesis while enhancing osteoclast activity via nitric oxide and interleukin-1β-mediated signaling pathways.
    Gramoun A; Azizi N; Sodek J; Heersche JN; Nakchbandi I; Manolson MF
    J Cell Biochem; 2010 Nov; 111(4):1020-34. PubMed ID: 20672308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
    Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
    J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient retention of endochondral cartilaginous matrix with bisphosphonate treatment in a long-term rabbit model of distraction osteogenesis.
    Smith EJ; McEvoy A; Little DG; Baldock PA; Eisman JA; Gardiner EM
    J Bone Miner Res; 2004 Oct; 19(10):1698-705. PubMed ID: 15355565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
    Tai TW; Su FC; Chen CY; Jou IM; Lin CF
    Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts.
    Suzuki K; Zhu B; Rittling SR; Denhardt DT; Goldberg HA; McCulloch CA; Sodek J
    J Bone Miner Res; 2002 Aug; 17(8):1486-97. PubMed ID: 12162503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial.
    Dalbeth N; Pool B; Stewart A; Horne A; House ME; Cornish J; Reid IR
    Calcif Tissue Int; 2013 Jan; 92(1):1-5. PubMed ID: 23052228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histochemical evidence of IGF2 mRNA-binding protein 2-mediated regulation of osteoclast function and adhesive ability.
    Liu H; Li D; Liu S; Liu Z; Li M
    Histochem Cell Biol; 2018 Apr; 149(4):343-351. PubMed ID: 29322325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.